We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 18, 2021

Gefitinib vs Cisplatin Plus Vinorelbine for Resected Stage II–IIIA EGFR-Mutated NSCLC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
J. Clin. Oncol 2021 Nov 02;[EPub Ahead of Print], H Tada, T Mitsudomi, T Misumi, K Sugio, M Tsuboi, I Okamoto, Y Iwamoto, N Sakakura, S Sugawara, S Atagi, T Takahashi, H Hayashi, M Okada, H Inokawa, H Yoshioka, K Takahashi, M Higashiyama, I Yoshino, K Nakagawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading